Guardant's Shield blood test more than triples volume to 83,000 tests a quarter

A year ago Guardant Health ran 24,000 Shield tests in a quarter. Last quarter it ran 83,000. The colorectal cancer screening blood test drove a strong third quarter, reported on 5 November, in which total revenue rose 36% to $361.0 million.

Where the growth came from

Screening revenue came in at $67.6 million, up 180% from $24.1 million. Oncology, still the biggest business, grew 25% to $231.3 million on test volume of 117,000, up 58%. Biopharma and data added $59.0 million, up 8%.

Get The Sequence every TuesdayThree-minute read. Free. One-click unsubscribe.

"Shield continued to build momentum in the third quarter, with volume more than tripling year over year to 83,000 tests," AmirAli Talasaz, co-founder and co-CEO, Guardant Health

Coverage is doing a lot of the work. Guardant says commercial coverage for Shield now reaches more than 80% of eligible lives, with UnitedHealth Group, Carelon Healthcare Services and EviCore among the recent additions, and that recent policy updates extend coverage to roughly 100 million lives. It has also fully rolled out a lower-cost, higher-throughput Shield workflow, which matters when volumes are climbing this quickly.

Regulatory progress

On the oncology side, Guardant360 CDx won FDA approval as a companion diagnostic for AstraZeneca's camizestrant, which the company calls the first FDA-approved liquid biopsy companion diagnostic for longitudinal testing in breast cancer. A second companion diagnostic approval followed for imlunestrant used with abemaciclib. Guardant has also submitted a premarket approval application for Guardant360 Tissue, and Guardant Reveal Ultra has launched with biopharma partners, with a clinical launch still planned for 2026.

The numbers and the outlook

Full-year revenue guidance rises to $1.36 billion to $1.37 billion, or 38% to 40% growth, from $1.34 billion to $1.36 billion. Screening guidance moves up to $233 million to $238 million on 285,000 to 290,000 Shield tests, and oncology volume growth is now expected to top 50%.

Guardant is also spending more to get there. The net loss widened to $124.4 million from $92.7 million, non-GAAP operating expense guidance rises to $1.105 billion to $1.125 billion, and expected free cash flow burn widens to $205 million to $220 million.

The bigger picture

Blood-based screening has moved from a promising idea to a business with real volume and real payer coverage. That changes the job: running a screening test at scale looks more like a consumer health operation, with primary care reach, patient outreach and lab throughput all mattering as much as the science.

What it means for hiring

Screening volume tripling in a year points to demand for primary care sales teams, health system and payer account leaders, and people who've sold a screening product rather than a specialist oncology test.
Higher opex guidance alongside a lower-cost workflow suggests investment in lab operations. Lab directors, automation engineers and operations leaders who have scaled high-throughput clinical labs are likely to be in demand.
A run of companion diagnostic approvals keeps biopharma partnering, regulatory affairs and CDx programme managers valuable across liquid biopsy, in our view.

Share Ask Eric about this →